Related Experiment Videos
Navigating the maze of newborn screening
Joanna K Spahis1, Nancy R Bowers
1M4 Genetics, Children's Medical Center, Dallas, TX, USA. Joanna.Spahis@childrens.com
Summary
Newborn screening identifies infants with genetic and metabolic diseases using advanced technology. Healthcare providers must understand screening policies, conditions, and parental education for informed decision-making.
Area of Science:
- Medical Genetics
- Public Health
- Neonatal Care
Background:
- Newborn screening in the U.S. began in the 1960s for phenylketonuria (PKU).
- Tandem mass spectrometry in the 1990s expanded screening to over 30 metabolic disorders.
- State-funded programs vary based on condition severity, prevalence, and treatment availability.
Purpose of the Study:
- To review the evolution and scope of newborn screening programs.
- To highlight the ethical considerations in newborn screening.
- To outline the essential knowledge for nurses caring for newborns and their families.
Main Methods:
- Review of historical development of newborn screening.
- Analysis of factors influencing state screening program inclusion.
- Discussion of ethical issues and nursing responsibilities.
Main Results:
- Newborn screening has evolved significantly with technological advancements.
- State-specific factors and ethical considerations impact screening programs.
- Nurses require comprehensive knowledge for effective parental counseling.
Conclusions:
- Newborn screening is crucial for early detection of genetic and metabolic diseases.
- Ethical disparities and policy inconsistencies require attention.
- Nurses play a vital role in ensuring informed parental consent and care coordination.